Evidence map›Paper›PMID 40990024›Full record

ReviewFrontiers in immunology2025

The feasibility of targeting macrophage for disease treatment: roles of CEBPD.

Tian Fan, Shaoling Lin, Jingjing Zhou, Jia Chen, Lexun Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tian FanSchool of Life Sciences, Guangzhou University, Guangzhou, China.
Shaoling LinGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangzhou, Guangdong, China.
Jingjing ZhouBeijing Key Laboratory of Maternal-Fetal Medicine and Fetal Heart Disease & Echocardiography Department, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jia ChenSchool of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
Lexun WangGuangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As ubiquitous innate immune cells, macrophages are crucial for tissue homeostasis and disease pathogenesis. Although our understanding of macrophage subsets and functions has advanced, no effective strategies are available for targeting macrophages to treat diseases in clinical settings due to their heterogeneity. Transcription factors that regulate macrophage function have received increasing attention. CCAAT/enhancer-binding protein delta (CEBPD), an inflammation-associated transcription factor characterized by low basal expression but rapid induction by stimuli, has emerged as a key regulator of macrophages. CEBPD governs diverse biological processes in macrophages through its target genes. Furthermore, macrophage CEBPD significantly contributes to various pathologies. Modulating CEBPD expression or activity in macrophages could regulate various molecular processes to improve disease progression and alleviate organ damage; therefore, novel CEBPD-based therapeutic methods for treating diseases have attracted attention. In this review, we describe the factors upstream and downstream of CEBPD in macrophages. We then summarize recent advances in the regulation of macrophage biological processes by CEBPD. Finally, we discuss the contribution of macrophage CEBPD to various diseases and highlight strategies for developing novel therapies to modulate macrophage function by targeting CEBPD.

Indexed as

CCAAT-Enhancer-Binding Protein-deltaMacrophagesAnimalsGene Expression RegulationHumansCCAAT-Enhancer-Binding Protein-deltaatherosclerosisCEBPDmacrophageosteoporosisphagocytosispolarization

Identifiers

PMID40990024
PMCPMC12450702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.